Vitamin B3 supplements shows promise for glaucoma patients in world-first clinical trial
A world-first crossover randomised clinical trial that backs up previous studies has found vitamin B3 nicotinamide could stop the onset of glaucoma and may even reverse blindness. High doses of vitamin B3 (3,000 mg) was also found to improve vision in people already suffering from a loss of sight.
Results of the trial, led by Professor Jonathan Crowston and Dr Flora Hui at the Centre for Eye Research Australia, are published today in Clinical and Experimental Ophthalmology. They show ‘significant improvement’ in the visual function of glaucoma patients who received a daily high dose of 3 grams of nicotinamide for 12 weeks in addition to their regular treatment to reduce eye pressure.